Article info
PDFClinical and epidemiological research
Extended report
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
- Correspondence to Professor Edward C Keystone, The Rebecca MacDonald Centre for Arthritis and Autoimmunity, Mt Sinai Hospital, University of Toronto, Toronto, Canada; ed.keystone{at}sinaihealthsystem.ca
Citation
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
Publication history
- Received February 3, 2017
- Revised June 22, 2017
- Accepted June 24, 2017
- First published August 10, 2017.
Online issue publication
January 09, 2022
Article Versions
- Previous version (1 November 2019).
- Previous version (1 November 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/